Login / Signup

Discovery of Bispecific Lead Compounds from Azadirachta indica against ZIKA NS2B-NS3 Protease and NS5 RNA Dependent RNA Polymerase Using Molecular Simulations.

Sanjay KumarSherif Aly El-KafrawyShiv BharadwajS S MaitraThamir A AlandijanyArwa A FaizoAiah M KhatebVivek Dhar DwivediEsam Ibraheem Azhar
Published in: Molecules (Basel, Switzerland) (2022)
Zika virus (ZIKV) has been characterized as one of many potential pathogens and placed under future epidemic outbreaks by the WHO. However, a lack of potential therapeutics can result in an uncontrolled pandemic as with other human pandemic viruses. Therefore, prioritized effective therapeutics development has been recommended against ZIKV. In this context, the present study adopted a strategy to explore the lead compounds from Azadirachta indica against ZIKV via concurrent inhibition of the NS2B-NS3 protease (ZIKV pro ) and NS5 RNA dependent RNA polymerase (ZIKV RdRp ) proteins using molecular simulations. Initially, structure-based virtual screening of 44 bioflavonoids reported in Azadirachta indica against the crystal structures of targeted ZIKV proteins resulted in the identification of the top four common bioflavonoids, viz. Rutin, Nicotiflorin, Isoquercitrin, and Hyperoside. These compounds showed substantial docking energy (-7.9 to -11.01 kcal/mol) and intermolecular interactions with essential residues of ZIKV pro (B:His 51 , B:Asp 75 , and B:Ser 135 ) and ZIKV RdRp (Asp 540 , Ile 799 , and Asp 665 ) by comparison to the reference compounds, O7N inhibitor (ZIKV pro ) and Sofosbuvir inhibitor (ZIKV RdRp ). Besides, long interval molecular dynamics simulation (500 ns) on the selected docked poses reveals stability of the respective docked poses contributed by intermolecular hydrogen bonds and hydrophobic interactions. The predicted complex stability was further supported by calculated end-point binding free energy using molecular mechanics generalized born surface area (MM/GBSA) method. Consequently, the identified common bioflavonoids are recommended as promising therapeutic inhibitors of ZIKV pro and ZIKV RdRp against ZIKV for further experimental assessment.
Keyphrases